Nivalin (Galantamine Hydrobromide)

Galantamine works by reversibly inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine, and by allosterically modulating nicotinic acetylcholine receptors. This dual action raises acetylcholine levels in the central nervous system, supporting memory and attention processes that are impaired in Alzheimer’s disease.

The specific dose of Nivalin is determined by the prescribing clinician based on the patient’s clinical condition, age, renal and hepatic function, and tolerance. Dosage adjustments are made during treatment to achieve optimal therapeutic benefit while minimizing side effects.

Safety data for galantamine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician after a thorough risk‑benefit assessment.

To request Nivalin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nivalin (galantamine) belongs to the acetylcholinesterase inhibitor class, similar to donepezil and rivastigmine. Compared with these agents, galantamine also offers allosteric modulation of nicotinic receptors, which may provide additional cognitive benefits in some patients, though individual response varies.

Nivalin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Nivalin is supplied as an injectable solution and can be given by intramuscular, intravenous, or subcutaneous injection. Administration technique and site selection are determined by the healthcare professional according to clinical guidelines and patient needs.

Serious risks include bradycardia, severe vomiting, hepatic enzyme elevation, seizures, and rare anaphylactic reactions. Patients should be monitored for cardiovascular symptoms, liver function changes, and any signs of allergic response throughout therapy.

Nivalin is contraindicated in patients with known hypersensitivity to galantamine or any formulation components, those with severe cardiac conduction disorders, uncontrolled asthma, or active peptic ulcer disease. Clinicians should also avoid use in patients taking strong anticholinergic agents that could negate its effect.